Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress

Chih Wei Lin, Jen Yi Lee, Yeou Ping Tsao, Che Piao Shen, Hung Cheng Lai, Show Li Chen

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Listeria monocytogenes is a Gram-positive, facultative intra-cellular bacterium with the ability to present secreted proteins to the major histocompatibility complex class I pathway to stimulate cell-mediated immune response. In our study, we constructed the recombinant L. monocytogenes encoding human papillomavirus type 16 E7 gene (rLM-E7). When orally administered to syngeneic mice, rLM-E7 could induce a cytotoxic T-lymphocyte (CTL) response. Furthermore, in vitro flow cytometric assay and in vivo immune deficiency assays showed that rLM-E7 could prevent and eradicate tumor growth via CD8+-dependent CTLs. Hence, the potency of rLM-E7 as a therapeutic vaccine for cervical cancer is the result of the induction E7-specific cell-mediated immunity by L. monocytogenes. In addition to potency, this vaccine also offers ease of administration and reduced cost of production compared with other vaccines formulated for injection. Thus, L. monocytogenes encoding HPV-16 E7 may be a useful oral vaccine for cervical cancer treatment.

Original languageEnglish
Pages (from-to)629-637
Number of pages9
JournalInternational Journal of Cancer
Volume102
Issue number6
DOIs
Publication statusPublished - Dec 20 2002
Externally publishedYes

Keywords

  • E7
  • HPV-16
  • Listeria
  • Oral vaccine
  • Tumor vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress'. Together they form a unique fingerprint.

  • Cite this